Q1 EPS Estimates for Pyxis Oncology Lifted by HC Wainwright

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2025 EPS estimates for shares of Pyxis Oncology in a report released on Wednesday, March 19th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.29) per share for the quarter, up from their previous estimate of ($0.38). HC Wainwright currently has a "Buy" rating and a $5.00 target price on the stock. The consensus estimate for Pyxis Oncology's current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Pyxis Oncology's Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.34) EPS, FY2026 earnings at ($1.25) EPS, FY2027 earnings at ($1.17) EPS, FY2028 earnings at ($0.53) EPS and FY2029 earnings at $0.24 EPS.

Separately, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $8.00 target price on shares of Pyxis Oncology in a research report on Wednesday, March 19th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $9.20.

Pyxis Oncology Stock Down 4.2 %

NASDAQ PYXS traded down $0.05 on Friday, reaching $1.15. The stock had a trading volume of 508,048 shares, compared to its average volume of 743,078. Pyxis Oncology has a 12-month low of $0.99 and a 12-month high of $6.18. The stock has a fifty day moving average price of $1.32 and a two-hundred day moving average price of $2.33. The firm has a market capitalization of $70.83 million, a price-to-earnings ratio of -1.12 and a beta of 1.11.

Remove Ads

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.01. The business had revenue of $16.15 million for the quarter.

Hedge Funds Weigh In On Pyxis Oncology

Several hedge funds have recently made changes to their positions in the company. Millennium Management LLC boosted its position in shares of Pyxis Oncology by 53.8% in the 4th quarter. Millennium Management LLC now owns 2,980,906 shares of the company's stock valued at $4,650,000 after purchasing an additional 1,043,228 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Pyxis Oncology by 5.5% in the third quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company's stock valued at $3,982,000 after acquiring an additional 57,016 shares during the period. State Street Corp grew its position in shares of Pyxis Oncology by 28.0% during the third quarter. State Street Corp now owns 951,251 shares of the company's stock worth $3,491,000 after acquiring an additional 208,344 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in shares of Pyxis Oncology by 57.2% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 601,940 shares of the company's stock valued at $939,000 after acquiring an additional 219,100 shares during the period. Finally, Ridgeback Capital Investments L.P. purchased a new stake in Pyxis Oncology in the 4th quarter valued at $560,000. Hedge funds and other institutional investors own 39.09% of the company's stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.